21世纪经济报道记者武瑛港实习生张烁李依浓北京报道 近日多家医疗器械上市公司发布业绩预告,行业的“寒冬”似乎仍在持续。 乐普医疗和春立医疗的利润大幅下滑,第三方医学检验龙头企业达安基因、金域医学和迪安诊断均由盈转亏,心脉医疗的营收和利润仍在增长,但增速明显下滑。 截至2月5日,已有257家A股上市药械企业披露2024年业绩预告,其中有121家企业预计亏损,亏损额合计逾300亿元。 早在...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.